Please assess the completion status of the following clinical trial:

Trial Title: Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons aged 15 - 65 years old~* Presenting with mild to moderate, non-bloody, acute diarrhea (≥3 loose stools/day for \<3 days) to participating health care settings~* For whom the study physicians recommend antimicrobial treatment~Exclusion Criteria:~* Is pregnant~* Requires hospitalization~* Has signs or symptoms of septicemia~* Has a primary complaint of another acute illness~* Has a serious chronic illness~* Has an allergy to aspirin~* Has been exposed to antimicrobial or antidiarrheal medications within 72 hours of enrollment~* Previously enrolled in study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Bismuth subsalicylate (Type: EXPERIMENTAL): Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.

Based on this trial design, predict the completion outcome and termination type (if applicable).